Aankondiging • Jun 09
Ixico plc Announces Appointments on Scientific Advisory Board IXICO plc had appointed Professor Jeffrey Cummings, MD, ScD, University of Nevada Las Vegas, Professor Charles DeCarli, MD, University of California, and Professor Stéphane Lehéricy, MD, Paris Brain Institute, to its Scientific Advisory Board. Professor Jeffrey Cummings is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr Cummings is globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. Dr Cummings interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. He has authored or edited 43 books and published over 800 peer-reviewed papers. Dr Cummings was formerly Augustas Rose Professor of Neurology and Professor of Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA, and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. He is past president of the Behavioural Neurology Society and of the American Neuropsychiatric Association. Professor Charles DeCarli is Distinguished Professor of Neurology at the University of California in Davis, California and recipient of the Victor and Genevieve Orsi Chair in Alzheimer's Research. He is Co-Director of the UC Davis Alzheimer's Disease Research Center (UCD ADRC), a United States National Institutes of Health funded Alzheimer's research centre. He is also Chief of the Imaging of Dementia and Aging (IDeA) laboratory. His research focuses on using advanced structural and functional brain imaging to study normal aging, mild cognitive impairment and dementia and the role of genetics, diversity, cerebrovascular and Alzheimer's disease on these processes. He is a recipient of the J. Allyn Taylor International Prize in Medicine-Imaging of the Aging Brain in recognition of his work. Professor Stéphane Lehéricy is Professor of Neuroradiology and head of the neuroradiology department at the Pitié-Salpêtrière Hospital (Paris) and Director of CENIR (Centre de neuro-imagerie de recherche) at the Paris Brain Institute. His area of research is the structural and functional study of the normal and pathological human brain, including movement pathology and neurodegenerative dementia. He focuses on the functional anatomy of the ganglia at the base of the normal human brain and on movement disorders. He has contributed to the understanding of the functional anatomy of the basal ganglia using fMRI and the diffusion tensor. Reported Earnings • May 25
First half 2026 earnings released: UK£0.012 loss per share (vs UK£0.011 loss in 1H 2025) First half 2026 results: UK£0.012 loss per share (further deteriorated from UK£0.011 loss in 1H 2025). Revenue: UK£3.95m (up 23% from 1H 2025). Net loss: UK£1.12m (loss widened 17% from 1H 2025). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Aankondiging • May 21
IXICO plc Reaffirms Earnings Guidance for the Full Year 2026 IXICO plc reaffirmed earnings guidance for the full year 2026. For the year, the company remains focused on delivering on guidance of 15% revenue growth. New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.8m net loss in 2 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (UK£18.8m market cap, or US$25.2m). Aankondiging • May 13
IXICO Plc Releases Latest Version Of AI-Driven Neuroimaging Technology Platform IXICO plc announced the latest version (v.10) of IXI™, IXICO's proprietary AI enabled neuroimaging platform that delivers clinical trial imaging and biomarker insights in neurological disease research. The IXI™ 10.0 release brings advances in image reading precision and analysis, enables larger and faster image data processing, and integrates new tools for remote image access and data quality qualification. The latest generation of IXI™ lays the foundation for IXICO's technology to move beyond its traditional iCRO remit as part of the Group's TechBio strategy. The strategy is focused on increasing IXICO's addressable market by enabling external organizations to directly access IXICO's technology via licensing, technology integration and partnering models such as the recently announced collaboration with Medidata (26 March 2026). Designed by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer's, Parkinson's, Huntington's and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis. IXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the drug development process via a single end to end platform. New Risk • Apr 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 135% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£2.8m net loss in 2 years). Market cap is less than US$100m (UK£15.3m market cap, or US$20.7m). Aankondiging • Apr 22
Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026 Ixico plc provided earnings guidance for the first half ended 31 March 2026. For the period, Revenues expected to be up 23% to £3.9 million (First half of 2025: £3.2m), driven by new contract wins, contract extensions and an increased volume of analyses in first half of 2026 relative to the equivalent prior period. Aankondiging • Apr 21
IXICO plc to Report First Half, 2026 Results on May 19, 2026 IXICO plc announced that they will report first half, 2026 results on May 19, 2026 Aankondiging • Apr 08
IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million. IXICO plc has completed a Follow-on Equity Offering in the amount of £0.03032 million.
Security Name: Ordinary shares
Security Type: Common Stock
Securities Offered: 379,000
Price\Range: £0.08
Transaction Features: Regulation S Major Estimate Revision • Apr 07
Consensus EPS estimates upgraded to UK£0.016 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -UK£0.018 to -UK£0.016 per share. Revenue forecast steady at UK£7.51m. Life Sciences industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target of UK£0.26 unchanged from last update. Share price was steady at UK£0.079 over the past week. Aankondiging • Feb 26
IXICO plc Presents Automated Capabilities to Measure Brain Volume Loss on Magnetic Resonance Imaging (MRI) Within its IXI Platform IXICO plc announced it has presented new demonstrating that automated capabilities to measure brain volume loss on magnetic resonance imaging (MRI) within its IXI Platform are at a minimum matching, and in some measures exceeding, the performance of semi-manual methods which require manual analysis by (human) experts. The accurate measurement of brain volume shrinkage (brain atrophy), caused by the loss of brain cells and the breakdown of connections between them, is fundamental to developing new treatments for a number of neurodegenerative diseases, including Huntington's Disease (HD). Traditionally, researchers have relied on a semi-manual approach to measure brain volume loss, known as the Boundary Shift Integral (BSI) which is currently considered to be the 'gold standard' method of analysis. In a recent study conducted by IXICO and a large US pharmaceutical partner, the results show that automated capabilities to measure brain atrophy on MRI within its IXI Platform match or exceed the performance of the semi-manual BSI method, providing an advanced, cost-effective and scalable solution to support clinical trials in HD. Of the three approaches evaluated to measure brain atrophy, IXICO demonstrated it was the most sensitive method for detecting whole brain and caudate (a small region deep in the brain impacted early in HD) volume loss. New Risk • Feb 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.07m (US$9.54m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£7.07m market cap, or US$9.54m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.6m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Aankondiging • Feb 06
IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer IXICO plc announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA). Tanya joins IXICO from Perceptive Inc., a global contract research organisation (CRO) where she held the role as SVP Commercial. Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi. Reported Earnings • Dec 10
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: UK£0.018 loss per share (improved from UK£0.041 loss in FY 2024). Revenue: UK£6.53m (up 13% from FY 2024). Net loss: UK£1.65m (loss narrowed 18% from FY 2024). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates by 23%. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 62% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (UK£11.4m market cap, or US$15.1m). Aankondiging • Dec 09
IXICO plc, Annual General Meeting, Jan 23, 2026 IXICO plc, Annual General Meeting, Jan 23, 2026. Location: cct venues smithfield, two east poultry avenue, smithfield, ec1a 9pt, london United Kingdom New Risk • Dec 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£2.1m net loss next year). Market cap is less than US$100m (UK£9.96m market cap, or US$13.3m). Aankondiging • Dec 01
IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025 IXICO plc announced at the CTAD conference held on December 1, 2025, that it has appointed two leading global experts in the field of Alzheimer's Disease (AD) and cerebrovascular disease (CVD) as advisors to the Company. Professor Michael Weiner, and Professor Joanna Wardlaw join IXICO's advisory board with immediate Effective December 1, 2025. Michael Weiner, MD, is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer's disease and other brain disorders. Recently he has focused on developing voice agents for assessments in AD clinical trials. Michael is the Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative, a 19-year national longitudinal study of over 3,500 subjects which is aimed at validating biomarkers for Alzheimer's disease at 63 sites across the USA and Canada for cognitive testing, MRI, PET, and lumbar puncture. He also launched the BrainHealthRegistry.org which is an internet-based registry with the overall goal of accelerating development of effective treatments for brain diseases. This website registry recruits, screens, and longitudinally monitors brain function on more than 100,000 participants. Dr. Weiner has mentored over 200 postdoctoral fellows, has authored over 1000 peer reviewed research papers and 71 book chapters. Joanna is ais Professor of Applied Neuroimaging at the University of Edinburgh, Foundation Chair of the UK DRI at Edinburgh, Director of the Row Fogo Centre for research into Ageing and the Brain, and Consultant Neuroradiologist for NHS Lothian. Her work focuses on understanding the brain and its blood supply, and treatments to improve blood flow to the brain, including thrombolytic drugs that are now in routine use to treat stroke, and more recently treatments for small vessel disease and vascular dementia. Working with many colleagues, she has been instrumental in advancing understanding of the causes of cerebral small vessel disease and is now testing treatments in clinical trials. She has set up national research imaging facilities, co-ordinated international research networks, advanced stroke care worldwide and published over 1000 papers. A Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences, she has received awards from many UK and international brain and heart organizations and was made a Commander of the Order of the British Empire (CBE) for services to Medicine and Neuroscience in 2016. Aankondiging • Nov 27
IXICO plc to Report Fiscal Year 2025 Results on Dec 09, 2025 IXICO plc announced that they will report fiscal year 2025 results on Dec 09, 2025 New Risk • Jul 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£2.1m net loss next year). Market cap is less than US$100m (UK£10.4m market cap, or US$14.0m). Aankondiging • Jun 10
IXICO plc Announces FDA Clearance of New Alzheimer's Disease Blood Based Diagnostic Biomarker IXICO plc outlined its role in the validation of a new Alzheimer's Disease (AD) diagnostic biomarker for client Fujirebio Diagnostics Inc. ("Fujirebio"), a global leader in the field of high-quality in vitro diagnostic (IVD) testing. The imaging analysis, conducted via IXICO's AI-driven platform, has supported Fujirebio's 510(k) FDA clearance for a new blood-based test that will help advance diagnosis and drug development in AD. The analysis included datasets from the Global Alzheimer's Platform Foundation's Bio-Hermes-001 study, of which both Fujirebio and IXICO are partners. As Bio-Hermes' imaging partner, IXICO led the standardisation, collection and expert analysis of PET data which served as the gold standard assessment of amyloid pathology in Fujirebio's FDA filing. On 16 May Fujirebio announced that it received clearance for its Lumipulse®? G pTau 217/b-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology In adult patients, aged 50 or older, being evaluated for Alzheimer's disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid the identification of patients with amyloid pathology associated with AD. Fujirebio's FDA clearance is based on data from a multi-center clinical study of 499 individuals in which amyloid positivity derived from the Lumipulse G pTau217/ss-Amyloid 1- 42 Plasma Ratio has been shown to be sufficiently comparable with results obtained through amyloid PET scan or CSF tests. These findings indicate that the new blood test can reliably predict the presence or absence of amyloid pathology associated with Alzheimer's disease at the time of the test in patients who are cognitively impaired. The test is intended for patients presenting at a specialized care setting with signs and symptoms of cognitive decline. The results must be interpreted in conjunction with other patient clinical information. The analysis by IXICO corresponds to the announcement made by the Company on 27 February 2025 that it had won a contract with an, at the time, undisclosed multinational biotechnology company. IXICO is now able to confirm that this company was Fujirebio. The imaging element of the clinical trial conducted on behalf of Fujirebio marks an expansion in IXICO's neuroimaging biomarker analyses capabilities beyond therapeutic clinical trial assessment to the analysis and validation of clinical diagnostic biomarkers. Reported Earnings • May 26
First half 2025 earnings released: UK£0.011 loss per share (vs UK£0.029 loss in 1H 2024) First half 2025 results: UK£0.011 loss per share (improved from UK£0.029 loss in 1H 2024). Revenue: UK£3.21m (up 26% from 1H 2024). Net loss: UK£958.0k (loss narrowed 32% from 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (UK£10.4m market cap, or US$14.0m). New Risk • Mar 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.65m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Market cap is less than US$10m (UK£7.65m market cap, or US$9.90m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£1.8m net loss next year). Reported Earnings • Dec 05
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: UK£0.041 loss per share (further deteriorated from UK£0.024 loss in FY 2023). Revenue: UK£5.77m (down 14% from FY 2023). Net loss: UK£2.00m (loss widened 70% from FY 2023). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 10.0%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Aankondiging • Dec 05
IXICO plc, Annual General Meeting, Jan 24, 2025 IXICO plc, Annual General Meeting, Jan 24, 2025. Location: ixicos office, 4th floor griffin court, 15 long lane, ec1a 9pn, london United Kingdom Aankondiging • Nov 25
IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024 IXICO plc announced that they will report fiscal year 2024 results on Dec 04, 2024 New Risk • Oct 10
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Market cap is less than US$10m (UK£6.92m market cap, or US$9.03m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£2.0m net loss next year). Major Estimate Revision • Oct 09
Consensus estimates of losses per share improve by 16% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from UK£5.20m to UK£5.50m. EPS estimate increased from -UK£0.055 per share to -UK£0.046 per share. Life Sciences industry in the United Kingdom expected to see average net income decline 1.8% next year. Consensus price target of UK£0.24 unchanged from last update. Share price was steady at UK£0.09 over the past week. Aankondiging • Aug 14
Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024 Ixico plc provided revenue guidance for the year ending 30 September 2024. For the period, revenue is expected to be between £5.5 million and £5.9 million (2023: £6.7 million) reflecting growth of at least 20% in revenues across the second half of the year as compared to the first half (H1 2024: £2.5 million). Aankondiging • Aug 05
IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024 IXICO plc announced that Bram Goorden will be appointed as Chief Executive Officer of the Company from 19 August 2024. Bram has over 20 years of leadership experience in BioPharma and precision medicine, serving in roles where he has been instrumental in shaping commercial strategies for scale, growing revenues and ultimately enabling the realisation of shareholder value. He has strong CNS experience, and established networks within IXICO's target market bringing sector relevant strength to IXICO. Bram joins having recently held C-level roles at Eagle Genomics Limited where he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA Genetics Inc. where he expanded their US footprint and delivered key alliances with Pharma. In previous roles as VP International Business, he expanded Foundation Medicine Inc.'s global presence in precision medicine including programs with major BioPharma partners, and as division CEO of US-based Prometheus Laboratories he delivered shareholder value via the integration of the company into Nestle Health Science SA. Bram has also held senior management positions within UCB Pharma SA and Eli Lilly & Co, both in the field of CNS medicine. Bram's neuroscience experience is demonstrated at Board level through current and past roles at Mantis Photonics AB and Cerecin Inc. Bram started his career as a management consultant at Accenture. Bram's appointment follows the announcement made on 12 January 2024, of Giulio Cerroni's intention to retire from his role as CEO by the end of 2024. Giulio will step down as a director of the Company on 16 August 2024. Giulio continues to be available to the Company to support an orderly hand over. New Risk • May 22
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (UK£3.45m market cap, or US$4.38m). Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change). Aankondiging • May 08
IXICO plc to Report First Half, 2024 Results on May 21, 2024 IXICO plc announced that they will report first half, 2024 results on May 21, 2024 New Risk • Jan 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. Market cap is less than US$10m (UK£5.42m market cap, or US$6.88m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£1.2m net loss in 2 years). Share price has been volatile over the past 3 months (8.0% average weekly change). Aankondiging • Jan 13
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024 IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as Chief Executive Officer ("CEO") of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. The Board has begun the process to appoint a new CEO in line with its succession plan and will update the market in due course. Aankondiging • Jan 12
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024 IXICO plc announced that Giulio Cerroni has informed the Board of his intention to retire from his role as director of the Company by the end of 2024 in accordance with his notice period and to ensure a smooth handover of responsibilities. Reported Earnings • Dec 06
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: UK£0.024 loss per share (down from UK£0.021 profit in FY 2022). Revenue: UK£6.67m (down 23% from FY 2022). Net loss: UK£1.18m (down 214% from profit in FY 2022). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 6.2%. Revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 49% per year, which means it has not declined as severely as earnings. Aankondiging • Dec 05
IXICO plc, Annual General Meeting, Jan 25, 2024 IXICO plc, Annual General Meeting, Jan 25, 2024, at 10:30 Coordinated Universal Time. Location: CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London United Kingdom Aankondiging • Nov 27
IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023 IXICO plc announced that they will report fiscal year 2023 results on Dec 05, 2023 New Risk • Oct 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.86m (US$9.54m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Market cap is less than US$10m (UK£7.86m market cap, or US$9.54m). Minor Risk Profit margins are more than 30% lower than last year (1.8% net profit margin). Aankondiging • Oct 06
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees IXICO plc announced the appointment of Dr. Dipti Amin as an Independent Non-Executive Director of the Company with immediate effect. Dr. Amin is an experienced non-executive director and medically trained senior executive with extensive commercial, leadership and operational experience, in medicine, pharmacology and the highly regulated healthcare and research sectors. Dr. Amin spent over twenty years of her executive career at IQVIA, occupying senior positions in compliance, drug safety and medical affairs and will bring significant additional pharmaceutical and CRO experience to the Company. Dr. Amin currently sits on the Boards of the University of Hertfordshire and Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sectors. Dr. Amin will also be joining the Remuneration and Audit committees with immediate effect. New Risk • Sep 29
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 41% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Minor Risks Profit margins are more than 30% lower than last year (1.8% net profit margin). Market cap is less than US$100m (UK£9.19m market cap, or US$11.2m). Aankondiging • Sep 29
IXICO plc Provides Earnings Guidance for the Full Year of 2023 IXICO plc provided earnings guidance for the full year of 2023. For the year, the company expects revenue to be £6.5 million (2022: £8.6 million). This reduction on the prior period principally reflects the final year of impact of the previously announced early cessation of large client trials coupled with some delays in new client trial initiations. Reported Earnings • May 24
First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.004 profit in 1H 2022) First half 2023 results: UK£0.015 loss per share (down from UK£0.004 profit in 1H 2022). Revenue: UK£3.20m (down 18% from 1H 2022). Net loss: UK£725.0k (down 436% from profit in 1H 2022). Revenue is forecast to stay flat during the next 2 years compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings. Aankondiging • May 11
IXICO plc to Report First Half, 2023 Results on May 23, 2023 IXICO plc announced that they will report first half, 2023 results on May 23, 2023 Aankondiging • May 10
IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024 IXICO plc provided earnings guidance for six months to 31 March 2023 and full year of 2024. for the period, revenues expected to be £3.2 million for six months to 31 March 2023 (H1 2022: £3.9 million); Loss before interest, tax, depreciation, and amortisation to 31 March 2023 expected to be £0.6 million (H1 2022: £0.5 million profit).The Board reaffirmed market guidance for the full year and return to revenue growth in 2024. Aankondiging • Feb 07
IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024 IXICO plc provided revenue guidance for the year ending September 30, 2024. For the year, the company expects to achieve double digit revenue growth in the year to 30 September 2024. The Company has diversified its orderbook and the Board expects to see revenue growth in 2024 as it continues to build upon the contract and client wins of the last two years. This return to revenue growth will be a key step on the path back to profitability. Reported Earnings • Dec 08
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: UK£0.021 (down from UK£0.033 in FY 2021). Revenue: UK£8.64m (down 6.0% from FY 2021). Net income: UK£1.03m (down 35% from FY 2021). Profit margin: 12% (down from 17% in FY 2021). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) also surpassed analyst estimates by 38%. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Aankondiging • Dec 07
IXICO plc, Annual General Meeting, Jan 27, 2023 IXICO plc, Annual General Meeting, Jan 27, 2023, at 10:30 Coordinated Universal Time. Location: CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London London United Kingdom Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Senior Independent Director Mark Warne was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • May 25
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down UK£842.0k from profit in 1H 2021). Profit margin: (down from 17% in 1H 2021). The decrease in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Senior Independent Director Mark Warne was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Dec 08
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: EPS: UK£0.033 (up from UK£0.02 in FY 2020). Revenue: UK£9.19m (down 3.6% from FY 2020). Net income: UK£1.58m (up 65% from FY 2020). Profit margin: 17% (up from 10.0% in FY 2020). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 16%. Earnings per share (EPS) surpassed analyst estimates by 16%. Over the next year, revenue is expected to shrink by 5.6% compared to a 7.8% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 29
First half 2021 earnings released: EPS UK£0.018 (vs UK£0.01 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£4.91m (up 7.9% from 1H 2020). Net income: UK£842.0k (up 77% from 1H 2020). Profit margin: 17% (up from 10% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 121% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improved over the past week After last week's 22% share price gain to UK£1.02, the stock trades at a trailing P/E ratio of 50.4x. Average forward P/E is 43x in the Life Sciences industry in the United Kingdom. Total returns to shareholders of 204% over the past three years. Is New 90 Day High Low • Mar 15
New 90-day high: UK£1.08 The company is up 16% from a price of UK£0.93 on 15 December 2020. Outperformed the British market which is up 5.0% over the last 90 days. Lagged the Life Sciences industry, which is up 20% over the same period. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 23% share price gain to UK£1.08, the stock trades at a trailing P/E ratio of 53.4x, up from the previous P/E ratio of 43.5x. Average P/E is 45x in the Life Sciences industry in the United Kingdom. Total returns to shareholders over the past three years are 196%. Recent Insider Transactions Derivative • Mar 03
CEO & Director exercised options and sold UK£140k worth of stock On the 1st of March, Giulio Cerroni exercised 676.58k options at around UK£0.36, then sold 295k of the shares acquired at an average of UK£0.84 per share and kept the remainder. For the year to September 2020, Giulio's total compensation was 52% salary and 48% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since June 2020, Giulio's direct individual holding has increased from 109.60k shares to 491.33k. Company insiders have collectively sold UK£721 more than they bought, via options and on-market transactions in the last 12 months. Is New 90 Day High Low • Jan 23
New 90-day low: UK£0.86 The company is down 18% from its price of UK£1.05 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 34% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£2.34 per share. Analyst Estimate Surprise Post Earnings • Dec 03
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Over the next year, revenue is forecast to grow 5.0%, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Reported Earnings • Dec 03
Full year 2020 earnings released: EPS UK£0.02 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£9.53m (up 26% from FY 2019). Net income: UK£952.0k (up 120% from FY 2019). Profit margin: 10.0% (up from 5.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Nov 19
New 90-day high: UK£1.14 The company is up 64% from its price of UK£0.69 on 21 August 2020. The British market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Valuation Update With 7 Day Price Move • Oct 22
Market bids up stock over the past week After last week's 20% share price gain to UK£1.07, the stock is trading at a trailing P/E ratio of 72.2x, up from the previous P/E ratio of 60.3x. This compares to an average P/E of 57x in the Life Sciences industry in the United Kingdom. Total returns to shareholders over the past three years are 213%. Is New 90 Day High Low • Oct 22
New 90-day high: UK£1.07 The company is up 50% from its price of UK£0.71 on 24 July 2020. The British market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Sep 30
New 90-day high: UK£0.97 The company is up 31% from its price of UK£0.74 on 02 July 2020. The British market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.